23.9 C
Buenos Aires
miércoles 3 marzo 2021 07:59
Inicio Etiquetas Oncology

Etiqueta: Oncology

Novartis: voluntary redundancies in Argentina

Switzerland's Novartis aims to become a "boutique drugmaker". It's opened negotiations on voluntary redundancies at it looks to downsize its salesforce in Onco-hematology in Argentina. It aims to reduce a division of 25 medical sales representatives by 36%. Multinational drugmakers are steadily refining their portfolios to specialise in increasingly sophisticated niches. Following...

Catalent to build third Argentine plant

The Softgel specialist Catalent is expanding its capacity in Argentina. Led locally by Hernán Mellone, the company, which dominates the local softgel market, will invest an estimated US$ 5 million in a new plant. US softgel specialist Catalent hasn't been put off by the ongoing lockdown, nor the local...

Takeda sells 18 brands

English version Since Japan's Takeda acquired Shire in 2018, the drugmaker's course towards a specialist focus has been set. The sale of its portfolio of mature drugs has been predicted. Two local brands have changed hands for now as part of a deal with regional reach. Japan's Takeda has sold...

Helsinn signs regional deal

English version Switzerland's Helsinn has closed an agreement with Argentina's Varifarma and Brazil's Blanver for the exclusive licensing and representation of one of its pipeline products in the region. The product in question is the potential oncological drug pracinostat, currently at the development stage. Switzerland's Helsinn has signed exclusive distribution and license agreements with Argentina'sVarifarma and Brazil's Blanver through which the companies...

Novartis oncology, over and out

English version The team at Novartis Oncology in Argentina is waiting expectantly after learning that CEO Aliya Omer is moving on after barely a year in the country. Most of the team is said to have welcomed the news since Omer's particular management meant several had to move departments of even leave the company. We know the multinationals rotate...

IMS: Emerging markets, prices and perspectives

The IMS World Review 2014 took place today in Buenos Aires, at Puerto Salguero, in Costa Salguero exhibition center. English version The IMS World Review 2014 took place today in Buenos Aires, at Puerto Salguero, in Costa Salguero exhibition center. The event covered by Pharmabiz brought together the main members of the...

Novartis: new local head of oncology

English version Gustavo Gil has retired from Swiss drugmaker Novartis. He led the oncology division in Argentina for more than a decade. The American Aliya Omer takes his place. May will be a key month for Novartis’ local oncology business in Argentina, with section head Gustavo Gil stepping down after a decade in the position. The Argentine director, who is retiring, held...

Murray: global pharma perspectives

New Zealander Murray Aitken, Executive Director of IMS Institute for Healthcare Informatics, arrived in Argentina to give his global perspectives. English Version New Zealander Murray Aitken –Executive Director of IMS Institute for Healthcare Informatics- arrived in Argentina to give his global perspectives. Aitken explained which therapeutic areas were the most important and grew at the fastest...

Congress: prices, industry and more

Argentine president Cristina Fernández de Kirchner opened the 132nd assembly of the National Congress in Buenos Aires on Saturday, marking the start of the 2014 legislative sessions. English version  Argentine president Cristina Fernández de Kirchner opened the 132nd assembly of the National Congress in Buenos Aires on Saturday (March 1), marking the start of the 2014 legislative...

Pfizer: reestructuración internacional y local

El laboratorio número uno del mundo arrancó el 2009 con importantes novedades. Sucede que en el mes de enero la compañía puso en marcha una marcada reestructuración a nivel internacional. ¿Los principales cambios? La organización deja de ser territorial para alinearse detrás de seis principales unidades de negocio. Así, la firma...